Daptomycin Powder For Concentrate For Solution For Infution 350 Mg/500 Mg Dry Powder Injections Vial

What is Daptomycin Powder For Concentrate For Solution For Infution 350 Mg/500 Mg Dry Powder Injections Vial?

Daptomycin is a cyclic lipopeptide antibacterial agent used for selected infections caused by susceptible Gram-positive bacteria. It is supplied in a dry powder presentation that must be prepared according to the approved product instructions before administration. Its authorised indications, dosing, route, preparation method and storage requirements depend on the specific product information and applicable regulatory requirements.

Uses / Indications

Daptomycin is used for certain infections caused by susceptible Gram-positive bacteria. Depending on the approved product information, indications may include:

• Complicated skin and skin-structure infections.

• Staphylococcus aureus bloodstream infections (bacteraemia).

• Selected cases of right-sided infective endocarditis caused by susceptible S. aureus.

The exact indications vary by product label and jurisdiction. Daptomycin is not indicated for the treatment of pneumonia under the cited US prescribing information. Treatment should be guided by clinical assessment and microbiological susceptibility results.

6. Benefits

• Targeted antibacterial activity: Acts against susceptible Gram-positive bacteria.

• Defined injectable presentation: Supplied as dry powder for preparation according to approved instructions.

• Multiple stated strengths: The supplied product listing includes 350 mg and 500 mg presentations.

• Specialist clinical application: Provides a treatment option for certain serious bacterial infections when clinically appropriate.

• B2B pharmaceutical sourcing: Kelar Pharmachem India can support product enquiries, subject to confirmation of availability and applicable market requirements.

Daptomycin is not a universal substitute for other antibiotics, and its use requires appropriate clinical monitoring.

7. Side Effects

Common or recognised side effects

Reported adverse reactions can include:

• Gastrointestinal disturbances, including nausea or diarrhoea.

• Headache.

• Injection- or infusion-associated reactions.

• Increased creatine phosphokinase (CPK) levels.

• Muscle discomfort or weakness.

The frequency of these effects varies with the indication, patient population and treatment circumstances.

Less common or serious side effects

Important risks include:

• Myopathy and rhabdomyolysis: Muscle injury that may be associated with substantial CPK elevation.

• Eosinophilic pneumonia: A potentially serious lung reaction.

• Anaphylaxis and serious hypersensitivity reactions.

• Peripheral neuropathy: Nerve-related symptoms such as tingling or altered sensation.

• Clostridioides difficile-associated diarrhoea.

• Tubulointerstitial nephritis: A potentially significant inflammatory kidney reaction.

• DRESS: A serious drug reaction involving rash and possible systemic organ involvement.

Prompt medical assessment is necessary if serious adverse effects are suspected. Muscle symptoms and CPK levels should be monitored according to the approved product information.

8. How Does It Work?

Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes in a calcium-dependent manner. It disrupts membrane function, causing rapid depolarisation and inhibition of essential cellular processes, ultimately leading to bacterial cell death.

Its activity is directed primarily against susceptible Gram-positive bacteria. It should not be assumed to provide effective treatment against every Gram-positive organism or resistant strain.

9. Dosage Guidelines

Dosage must be determined by an appropriately qualified healthcare professional using the approved prescribing information for the specific product.

Factors affecting dosage include:

• The infection being treated and its severity.

• Patient age and body weight.

• Renal function.

• Microbiological susceptibility results.

• The prescribed treatment duration and clinical response.

Do not infer the dose, frequency, infusion duration, reconstitution volume, diluent, final concentration or post-reconstitution stability from the vial strength alone.

The exact preparation and administration instructions must be confirmed from the approved product documentation. The medicine should be administered by appropriately qualified healthcare professionals.

10. When Not to Use

Daptomycin should not be used in the following circumstances, subject to the exact approved product information:

• Known hypersensitivity to daptomycin or relevant formulation ingredients.

• Infections for which daptomycin is not an appropriate treatment.

• Situations where the causative organism is not susceptible or the product is not indicated.

Additional precautions may be required in patients with renal impairment, pre-existing muscle disorders or medicines that increase the risk of muscle injury. These situations require individual assessment rather than an assumption that every patient has an absolute contraindication.

11. Drug / Product Interactions

Potential interaction considerations include:

• Statins and other medicines associated with muscle injury: Concurrent use may require additional assessment and monitoring.

• Renally cleared medicines: Review is important where impaired kidney function or concurrent treatment may affect safety.

• Anticoagulants and laboratory monitoring: Assess the relevance of any monitoring-related concerns in the individual patient.

• Other injectable medicines: Physical compatibility must be confirmed before mixing or co-administration.

Healthcare professionals should review the patient’s full medication history and follow the product-specific interaction guidance. Do not mix daptomycin with another medicine in the same container unless compatibility is specifically confirmed.

12. Safety Advice

• Use only under qualified medical supervision.

• Confirm the product name, strength, batch number and expiry date before preparation.

• Review any history of hypersensitivity to daptomycin.

• Assess renal function and follow the required monitoring plan.

• Monitor for muscle pain, weakness or other signs of muscle injury.

• Report new respiratory symptoms promptly because eosinophilic pneumonia is a recognised serious risk.

• Seek urgent medical assessment for severe allergic reactions or significant muscle weakness.

• Do not use for self-medication or unsupervised administration.

13. General Instructions

• Inspect the vial and packaging for damage before use.

• Read the approved product label and package insert.

• Use the specified diluent and preparation method only.

• Follow appropriate aseptic preparation procedures.

• Do not assume compatibility with other medicines or infusion solutions.

• Check the prepared solution against the manufacturer’s specified acceptance criteria.

• Follow the approved instructions for use after reconstitution or dilution.

• Dispose of unused product and preparation materials in accordance with applicable procedures.

Preparation volumes, mixing technique, administration time, compatibility and stability after reconstitution must be verified against the exact manufacturer’s documentation. Different daptomycin formulations may have different instructions.

14. Special Dietary / Lifestyle Tips

No specific dietary regimen can be established from the supplied product details alone.

• Follow the prescribed treatment and monitoring schedule.

• Inform the treating healthcare professional about all medicines and supplements being used.

• Attend recommended blood tests and follow-up appointments.

• Report muscle pain, unexplained weakness, breathing difficulties or persistent diarrhoea promptly.

• Do not change, stop or repeat antibiotic treatment without medical advice.

15. Comparison with Other Treatments

Daptomycin is not interchangeable with other antibiotics solely because they treat bacterial infections. Selection depends on the organism, infection site, susceptibility data, patient-specific risks and applicable clinical guidance.

16. Precautions & Warnings

• Muscle toxicity: Monitor for muscle pain or weakness and follow the approved CPK-monitoring recommendations.

• Renal impairment: Assessment of kidney function is important and may affect dosage.

• Respiratory symptoms: Eosinophilic pneumonia is a recognised serious adverse reaction.

• Neurological symptoms: Report new tingling, numbness or other symptoms that may indicate peripheral neuropathy.

• Severe diarrhoea: Consider antibiotic-associated colitis and seek appropriate medical assessment.

• Hypersensitivity: Serious allergic reactions can occur.

• Paediatric use: Age-related restrictions and precautions must be checked against the approved product label.

• Antimicrobial resistance: Use only when clinically justified and in accordance with appropriate prescribing guidance.

These precautions should be assessed against the specific product information and the patient’s clinical circumstances.

17. Can I Use It With Other Medicines or Antibiotics?

Use with other medicines or antibiotics requires review by a qualified healthcare professional.

Before treatment, the clinician should assess:

• Current prescription and non-prescription medicines.

• Statins or other medicines associated with muscle injury.

• Renal function and medicines that may affect it.

• The clinical reason for combination antibiotic treatment.

• Compatibility with the intended diluent or infusion solution.

Clinical drug interactions and physical compatibility are separate considerations. Do not mix or co-administer injectable medicines without appropriate professional guidance and product-specific compatibility evidence.

18. Storage

Store according to the manufacturer’s approved product labelling. Refer to the product packaging or package insert for the applicable storage conditions.

The storage temperature, light-protection requirements, shelf life and stability after reconstitution or dilution have not been supplied for this specific product. Confirm them against the relevant manufacturer’s documentation before publication.

19. Frequently Asked Questions (FAQs)

1. What is Daptomycin Powder For Concentrate For Solution For Infusion used for?

It is used for selected infections caused by susceptible Gram-positive bacteria, including certain complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections, subject to the approved product indications.

2. What strengths are listed?

The supplied product name lists 350 mg and 500 mg presentations. Confirm the exact strengths against the approved product label.

3. Which antibiotic class does daptomycin belong to?

Daptomycin is a cyclic lipopeptide antibiotic, not a cephalosporin.

4. Which route of administration is used?

The cited US product information specifies intravenous administration. Confirm the approved route and method for the particular product before publication.

5. How should the dry powder be reconstituted?

Follow the specific manufacturer’s approved preparation instructions. The required diluent, reconstitution procedure and final concentration must not be assumed from the strength alone.

6. What monitoring may be needed during treatment?

Monitoring may include renal function, CPK levels and assessment for muscle symptoms or other clinically significant adverse effects, as directed by the treating healthcare professional.

7. How should the product be stored?

Follow the storage instructions on the approved product label. Storage conditions and stability after preparation must be confirmed for the specific formulation.

8. Is the product available for pharmaceutical export?

Availability, packing options, order quantities and destination-market documentation should be confirmed with Kelar Pharmachem India. This listing does not imply any specific regulatory approval or certification.